Literature DB >> 8777995

Regulation of low-density lipoprotein particle size distribution in NIDDM and coronary disease: importance of serum triglycerides.

S Lahdenperä1, M Syvänne, J Kahri, M R Taskinen.   

Abstract

An increase of low-density lipoprotein triglycerides (LDL-Tg) was found to be an independent coronary artery disease (CAD) risk factor for non-insulin-dependent diabetic (NIDDM) patients in a recent prospective study. We examined the composition and size of LDL particles in 50 NIDDM men with angiographically verified CAD (NIDDM+ CAD+) and in 50 NIDDM men without CAD (NIDDM(+)-CAD-) as compared to 50 non-diabetic men with CAD (NIDDM - CAD +) and 31 non-diabetic men without CAD (NIDDM-CAD-). The groups had similar ranges of age and BMI. LDL particle size was determined by gradient gel electrophoresis, and LDL was isolated by sequential ultracentrifugation for compositional analyses. Serum Tg was increased in NIDDM patients as compared to non-diabetic subjects (p < 0.05), and in patients with CAD as compared to subjects without the disease (p < 0.05). LDL cholesterol was lower in NIDDM patients than in non-diabetic subjects (p < 0.001). Mean diameter of LDL particles was less than 255 A, but closely comparable in all groups. The presence of NIDDM was associated with increases of Tg and protein but lowering of free cholesterol in LDL (p < 0.005 for all). In multivariate regression analyses neither NIDDM nor CAD were associated with LDL particle size, but serum Tg was the major determinant of LDL size in both NIDDM and non-diabetic subjects (p < 0.001). When the patients were divided into quartiles according to fasting serum Tg levels, the LDL particle size and free cholesterol content decreased, but Tg and protein contents of LDL particles increased from the lowest to the highest Tg quartile (analysis of variance p < 0.001 for all). When the subjects were categorized into two groups according to the median of VLDL-Tg (1.10 mmol/l) LDL size was associated with VLDL-Tg in the high but not in the low VLDL-Tg group. We conclude that in NIDDM patients with or without CAD serum Tg is the major determinant of the properties of LDL particles. The clinical implication is that in NIDDM serum Tg should be as low as possible to prevent atherogenic changes in LDL.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8777995     DOI: 10.1007/bf00400677

Source DB:  PubMed          Journal:  Diabetologia        ISSN: 0012-186X            Impact factor:   10.122


  54 in total

1.  Atherogenic lipoprotein phenotype. A proposed genetic marker for coronary heart disease risk.

Authors:  M A Austin; M C King; K M Vranizan; R M Krauss
Journal:  Circulation       Date:  1990-08       Impact factor: 29.690

2.  Susceptibility of small, dense, low-density lipoproteins to oxidative modification in subjects with the atherogenic lipoprotein phenotype, pattern B.

Authors:  A Chait; R L Brazg; D L Tribble; R M Krauss
Journal:  Am J Med       Date:  1993-04       Impact factor: 4.965

3.  Heterogeneity of plasma low density lipoproteins manifestations of the physiologic phenomenon in man.

Authors:  W R Fisher
Journal:  Metabolism       Date:  1983-03       Impact factor: 8.694

4.  Development and application of a multicompartmental model to study very low density lipoprotein subfraction metabolism.

Authors:  C J Packard; A Gaw; T Demant; J Shepherd
Journal:  J Lipid Res       Date:  1995-01       Impact factor: 5.922

Review 5.  Quantitative and qualitative lipoprotein abnormalities in diabetes mellitus.

Authors:  M R Taskinen
Journal:  Diabetes       Date:  1992-10       Impact factor: 9.461

6.  Clustering of heart disease risk factors in diabetic compared to nondiabetic adults.

Authors:  D L Wingard; E Barrett-Connor; M H Criqui; L Suarez
Journal:  Am J Epidemiol       Date:  1983-01       Impact factor: 4.897

7.  Plasma lipids and diabetes mellitus in an adult community.

Authors:  E Barrett-Connor; S M Grundy; M J Holdbrook
Journal:  Am J Epidemiol       Date:  1982-05       Impact factor: 4.897

8.  Low-density lipoprotein subclass patterns and risk of myocardial infarction.

Authors:  M A Austin; J L Breslow; C H Hennekens; J E Buring; W C Willett; R M Krauss
Journal:  JAMA       Date:  1988-10-07       Impact factor: 56.272

9.  High density lipoprotein subfractions in non-insulin-dependent diabetes mellitus and coronary artery disease.

Authors:  M Syvänne; M Ahola; S Lahdenperä; J Kahri; T Kuusi; K S Virtanen; M R Taskinen
Journal:  J Lipid Res       Date:  1995-03       Impact factor: 5.922

10.  HDLs containing apolipoproteins A-I and A-II (LpA-I:A-II) as markers of coronary artery disease in men with non-insulin-dependent diabetes mellitus.

Authors:  M Syvänne; J Kahri; K S Virtanen; M R Taskinen
Journal:  Circulation       Date:  1995-08-01       Impact factor: 29.690

View more
  18 in total

1.  Conway Memorial Lecture 2002. The dyslipidaemia of diabetes: lessons in the pathogenesis of atherosclerosis.

Authors:  G H Tomkin
Journal:  Ir J Med Sci       Date:  2002 Oct-Dec       Impact factor: 1.568

2.  Cholesteryl ester transfer protein (CETP) -629C/A polymorphism and it's effects on the serum lipid levels in metabolic syndrome patients.

Authors:  M Akbarzadeh; T Hassanzadeh; M Saidijam; R Esmaeili; Sh Borzouei; M Hajilooi; H Mahjub; M Paoli
Journal:  Mol Biol Rep       Date:  2012-06-23       Impact factor: 2.316

3.  The clinical biochemistry of obesity.

Authors:  Ken A Sikaris
Journal:  Clin Biochem Rev       Date:  2004-08

Review 4.  Diabetes: mellitus or lipidus?

Authors:  E Shafrir; I Raz
Journal:  Diabetologia       Date:  2003-03-14       Impact factor: 10.122

Review 5.  The role of CETP inhibition in dyslipidemia.

Authors:  Karim El Harchaoui; Wim A van der Steeg; Erik S G Stroes; John J P Kastelein
Journal:  Curr Atheroscler Rep       Date:  2007-08       Impact factor: 5.113

6.  Impaired fasting glucose and impaired glucose tolerance have distinct lipoprotein and apolipoprotein changes: the insulin resistance atherosclerosis study.

Authors:  Carlos Lorenzo; Sara Hartnett; Anthony J Hanley; Marian J Rewers; Lynne E Wagenknecht; Andrew J Karter; Steven M Haffner
Journal:  J Clin Endocrinol Metab       Date:  2013-02-28       Impact factor: 5.958

7.  Mechanism of inhibition defines CETP activity: a mathematical model for CETP in vitro.

Authors:  Laura K Potter; Dennis L Sprecher; Max C Walker; Frank L Tobin
Journal:  J Lipid Res       Date:  2009-03-11       Impact factor: 5.922

Review 8.  Diabetic dyslipidaemia: from basic research to clinical practice.

Authors:  M-R Taskinen
Journal:  Diabetologia       Date:  2003-05-28       Impact factor: 10.122

9.  Body mass index and glycemic control influence lipoproteins in children with type 1 diabetes.

Authors:  Shalini Vaid; Lynae Hanks; Russell Griffin; Ambika P Ashraf
Journal:  J Clin Lipidol       Date:  2016-08-06       Impact factor: 4.766

Review 10.  Dyslipidemia and diabetes: reciprocal impact of impaired lipid metabolism and Beta-cell dysfunction on micro- and macrovascular complications.

Authors:  Gianluca Bardini; Carlo M Rotella; Stefano Giannini
Journal:  Rev Diabet Stud       Date:  2012-11-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.